Home
puma biotechnology news, Is Puma off M&A list? With Nerlyx deal, some investors think | Fierce Pharma, PumaBiotech / Twitter
-
Biotechnology Executives Under for Breast Cancer Drug — Schubert Jonckheer & Kolbe
-
Prognosis For Biotechnology (NASDAQ:PBYI) | Seeking Alpha
-
Puma shares on drug but options smell 'fishy'
-
Puma Biotechnology Announces Publication of Phase II Clinical of Alisertib in JAMA Oncology | Business
-
Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
-
Puma Biotechnology STAT
-
Puma Bulls Win Monday's FDA Review, Ahead Wednesday's Advisory Panel Vote TheStreet
-
Stocks to Watch: Dropbox, Nike, Qualcomm, Puma Biotechnology, Invitation Homes, Universal Display - WSJ
-
Puma
-
Puma Biotech In-Licenses Takeda's Cancer Primary Focus On Breast & Lung Cancer
-
Biotechnology reports interim SUMMIT results neratinib | Drug Discovery News
-
Puma Inc.
-
Biotech gets panel nod for breast cancer drug, Health News, ET HealthWorld
-
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Patients 2L+ HER2+ Metastatic Cancer #ASCO2019
-
Puma (PBYI) Stock Climbs On Orphan Designation | Alpha Stock News
-
Goldman Sachs Group Cuts Puma Biotechnology (PBYI)
-
Why Puma Biotechnology, Inc. Crashed 37% in March | Fox Business
-
Puma Biotechnology Inc Price USD0.0001
-
Puma Surging
-
PumaBiotech / Twitter
-
Puma
-
PumaBiotech / Twitter
-
Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
-
Takeda enter licensing agreement for cancer treatment alisertib | Seeking
-
Puma
-
Puma Biotechnology, Inc. (PBYI) Price, Quote & - Stock
-
Biotechnology Inc (NASDAQ:PBYI) Share Price | RNS News, Quotes, & Charts |